Biotech Values

[rjmcanoe]

I would like to look closer to the Rx data for mLovenox. If mLovenox market share is 59% when it used to be 50%. This could be the reason Sanofi released their authorized generic lovenox rather than the approval of amphastars lovenox. It looks very unfair to me if Novartis pushed the market share of mlovenox to such a level that it forced Sanofi to launch their AG. This move certainly hurts Momenta more than it does Novartis if it hurts Novartis at all. Does anyone else see this as a reason for Sanofis AG launch.
Bob